• Molecular NamePemetrexed
  • SynonymLY231514; Pemetrexed Disodium
  • Weight427.417
  • Drugbank_IDDB00642
  • ACS_NO137281-23-3
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)0.38
  • pkaN/A
  • LogD (pH=7, predicted)-3.09
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)0.37
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.54
  • No.of HBond Donors7
  • No.of HBond Acceptors11
  • No.of Rotatable Bonds9
  • TPSA186.97
  • StatusFDA approved
  • AdministrationIntravenous
  • PharmacologyA chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma as well as non-small cell lung cancer.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding81.0
  • Volume of distribution (VD)0.23 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNegligible
  • Half life3.5 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A